Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dr Carol Davila Teaching Hospital of Nephrology Bucharest | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective single center randomized controlled trial with a total duration of 18 months aiming to evaluate the effectiveness and the safety of a very low protein diet supplemented with ketoanalogues of essential aminoacids in reducing the progression of chronic kidney disease (CKD) in patients with advanced CKD.
All eligible patients who will give informed consent will be screened. Those meeting the selection criteria will be enrolled and will enter a 3-month run-in phase during which a conventional LPD will be prescribed in all patients.
At the end of this phase, the subjects still fulfilling all the selection criteria will be randomized in a 1:1 ratio to receive the KD or to continue the conventional LPD for a total duration of 15 months.
Nineteen blood and urine samplings are scheduled for each patient, to be drawn monthly. The laboratory reports include the nitrogen compounds, calcium-phosphorus metabolism parameters, acid-base balance, biochemical nutritional markers, serum C-reactive protein, hemoglobin, blood cell count, and biochemical safety parameters (sodium, potassium, liver enzymes, and bilirubin).
The anthropometric measurements and subjective global assessment will be evaluated at enrolment, at randomization, and every 3 months thereafter.
The compliance with the prescribed diet (protein and energy intake) will be assessed monthly during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and every 3 months thereafter.
The blood pressure levels, drugs required for the therapy of hypertension, acidosis and mineral metabolism disorders, and occurrence of adverse events will be recorded monthly.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Keto-diet (KD) | Experimental | Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day. |
|
| Low Protein Diet group (LPD) | Active Comparator | The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins). The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Conventional low protein diet | Behavioral |
|
| |
| Measure | Description | Time Frame |
|---|---|---|
| Primary composite endpoint | Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate compared to randomization | 15 months after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary efficacy parameter | The rate of decline in the estimated Glomerular Filtration Rate | months 3-15 after randomization |
| Secondary outcome measure - nitrogen balance | variations in serum urea |
| Measure | Description | Time Frame |
|---|---|---|
| Compliance - protein intake | urinary urea nitrogen excretion to calculate the protein intake | 18 months after enrolment |
| Compliance - energy intake | 3-day food diary to calculate the daily energy intake |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gabriel Mircescu, Prof | Carol Davila University of Medicine and Pharmacy | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| "Dr Carol Davila" Teaching Hospital of Nephrology | Bucharest | 010731 | Romania |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17462550 | Result | Mircescu G, Garneata L, Stancu SH, Capusa C. Effects of a supplemented hypoproteic diet in chronic kidney disease. J Ren Nutr. 2007 May;17(3):179-88. doi: 10.1053/j.jrn.2006.12.012. | |
| 33118160 | Derived | Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 29;10(10):CD001892. doi: 10.1002/14651858.CD001892.pub5. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C048995 | ketosteril |
| D055423 | Diet, Ketogenic |
| ID | Term |
|---|---|
| D050528 | Diet, Carbohydrate-Restricted |
| D004035 | Diet Therapy |
| D044623 | Nutrition Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Very low protein diet supplemented with Ketosteril |
| Dietary Supplement |
|
|
| 15 months after randomization |
| Secondary efficacy parameter - mineral metabolism | variations in total serum calcium | 15 weeks after randomization |
| Secondary efficacy parameter | variations in serum phosphate level | 15 weeks after randomization |
| Secondary efficacy parameter | variations in serum bicarbonate | 15 weeks after randomization |
| Secondary safety parameter | Subjective Global Assessment of the nutritional status | 18 weeks after enrolment |
| Secondary safety parameter | Body Mass Index | 18 weeks after enrolment |
| Secondary outcome measure - Nutritional status | Tricipital skinfold | 18 weeks after enrolment |
| Secondary safety parameter - anthropometric measures | Mid-arm muscular circumference | 18 weeks after enrolment |
| Nutritional status - biochemical markers | serum albumin | 18 weeks after enrolment |
| Inflammation | serum level of C reactive protein | 18 weeks after enrolment |
| Nutritional status - biochemical marker | Serum total cholesterol | 18 weeks after enrolment |
| Secondary safety parameter | Serum potassium level | 18 weeks after enrolment |
| Secondary safety parameter | liver enzymes: Aspartate Aminotransferase, Alanine Transaminase | 18 weeks after enrolment |
| Safety parameter - adverse events | Occurrence of any adverse event | 18 weeks after enrolment |
| Secondary safety parameter - withdrawals | number of withdrawals | 18 weeks after enrolment |
| 18 weeks after enrolment |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D004032 |
| Diet |
| D009747 | Nutritional Physiological Phenomena |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |